Get the Stockscreener App
8.2557
7.69%
-0.7143
Mind Medicine Inc stock is traded at $8.2557, with a volume of 1.61M.
It is down -7.69% in the last 24 hours and up +2.10% over the past month.
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
See More
Previous Close:
$8.97
Open:
$8.87
24h Volume:
1.61M
Relative Volume:
0.95
Market Cap:
$657.79M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-3.3697
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
+21.94%
1M Performance:
+2.10%
6M Performance:
+13.27%
1Y Performance:
+95.74%
1-Day Range:
$8.13
$8.97
1-Week Range:
$6.48
$10.20
52-Week Range:
$4.18
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
8.23 | 657.79M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.06 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.44 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.71 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.65 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
FY2029 Earnings Forecast for MNMD Issued By HC Wainwright - MarketBeat
Analysts Set Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) PT at $26.33 - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Sees Large Volume IncreaseShould You Buy? - MarketBeat
FY2029 Earnings Estimate for MNMD Issued By HC Wainwright - MarketBeat
Mind Medicine’s LSD Therapy Could Revolutionize Anxiety Treatment – Is It a Buy? - PUNE.NEWS
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Up 5.5%What's Next? - MarketBeat
Mind Medicine (MNMD) Advances Groundbreaking LSD Treatment - TipRanks
BlackRock, Inc.'s Strategic Acquisition of Mind Medicine Inc Sha - GuruFocus.com
Leerink Partnrs Issues Negative Forecast for MNMD Earnings - MarketBeat
MindMed to Present at Oppenheimer Healthcare Conference - TipRanks
Inside MindMed's Next Big Move: Key Revelations Expected at Oppenheimer Healthcare Conference - StockTitan
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's Why - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Earns Outperform Rating from Analysts at Evercore ISI - MarketBeat
Q1 Earnings Estimate for MNMD Issued By Leerink Partnrs - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Mind Medicine (MindMed) (NASDAQ:MNMD) - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Now Covered by Analysts at Evercore ISI - MarketBeat
MindMed doses first subject in Phase III Panorama study of GAD tablet - Clinical Trials Arena
symbol__ Stock Quote Price and Forecast - CNN
Equities Analysts Set Expectations for MNMD Q1 Earnings - Defense World
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - The Globe and Mail
MindMed Initiates Second Phase 3 Study of MM120 for Anxiety - TipRanks
Mindmed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of Mm120 in Generalized Anxiety Disorder - Marketscreener.com
MindMed launches phase 3 trial for anxiety treatment - Investing.com
Revolutionary Anxiety Treatment: MindMed's LSD Therapy Enters Final Testing Stage - StockTitan
(MNMD) Trading Signals - Stock Traders Daily
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call (MNMD) - Seeking Alpha
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish - MSN
Evercore ISI Group Initiates Coverage of Mind Medicine (MNMD) with Outperform Recommendation - MSN
This Westlake Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder – Company Announcement - Financial Times
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Why Mind Medicine Stock Is Soaring Today - MSN
Where are the Opportunities in (MNMD) - Stock Traders Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 6.4%What's Next? - MarketBeat
Wealth Enhancement Advisory Services LLC Acquires 2,230 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Barclays PLC Has $775,000 Stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
MindMed gives more detail to investors in latest presentation - Green Market Report
Psychedelic drug developer Lykos could get lifeline from former Tesla board member - Seeking Alpha
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Mind Medicine Inc Reports Topline Data from Phase 1 Trial of MM-110 in Development for Treatment of Opioid Withdrawal - Marketscreener.com
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mind Medicine Inc Stock (MNMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Liao Carrie | Chief Accounting Officer |
Dec 26 '24 |
Sale |
7.43 |
2,273 |
16,888 |
97,270 |
| Karlin Dan | Chief Medical Officer |
Dec 26 '24 |
Sale |
7.43 |
6,643 |
49,357 |
338,013 |
| Sullivan Mark | Chief Legal Officer |
Dec 26 '24 |
Sale |
7.43 |
4,519 |
33,576 |
173,197 |
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):